Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14698321 | 0.83 | HPGD (0.45) | FAAHDDB1CRBNHPGDGPR119 | |
| SCHEMBL5494939 | 0.81 | HPGD (0.52) | HPGDGPR119KDM4EMAPTKMT2A | |
| SCHEMBL17469340 | 0.77 | HPGD (0.50) | HPGDGPR119KDM4EMEN1ALDH1A1 | |
| SCHEMBL12071961 | 0.77 | HPGD (0.50) | HPGDGPR119KDM4EMEN1ALDH1A1 | |
| SCHEMBL17776135 | 0.76 | NR1H2 (0.47) | DDB1CRBNHPGDKDM4EMEN1 | |
| SCHEMBL9014148 | 0.76 | KDM4E (0.46) | FAAHDDB1CRBNHPGDGPR119 | |
| SCHEMBL19658183 | 0.74 | CHRM2 (0.36) | KMT2A | |
| SCHEMBL18751701 | 0.74 | CHRM2 (0.36) | KMT2A | |
| SCHEMBL19658172 | 0.74 | CHRM2 (0.36) | KMT2A | |
| SCHEMBL18275003 | 0.74 | HPGD (0.43) | DDB1CRBNHPGDKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | FAAH 3297/4885DDB1 2303/4885CRBN 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.